Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Intranasal Dexmedetomidine and Esketamine in Children With ASD
NCT07324057Recruiting
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and esketamine in Autism Spectrum Disorder (ASD) (3 arms). Primary endpoint: Incidence of negative postoperative behavioral changes at 7 days. Started Apr 2026; status: recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07324057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324057.